Clinical Trial Update: First-line Regimen With QL1706 Plus Chemo ± Bev in PDAC Patients [Phase 2]

View source ↗

Summary

This entry describes an ongoing Phase 2 trial evaluating first-line therapy with QL1706 plus chemotherapy with or without bevacizumab in pancreatic cancer patie…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• QL1706

Snippet

Sponsor: Fudan University | Conditions: Pancreatic Cancer | Phase 2 | Status: RECRUITING